TUDCA is increasingly sold inside longevity stacks, usually next to compounds with the same problem: a handful of striking animal results, a mechanism that sounds plausible, and no human data on ageing at all.
The animal results here are real and some of them are genuinely interesting. What makes this page worth reading carefully is not whether they exist but how the compound was delivered in each one, because in two of the three key studies it did not go through the gut.
Key Takeaways
- In 18-month-old male mice given 300 mg/kg TUDCA, age-related hyperinsulinemia was attenuated and glucose homeostasis improved[1].
- The mechanism matters more than the headline. The improvement came from higher liver insulin-degrading enzyme expression and faster insulin clearance[1], which means insulin was being removed more quickly, not that the pancreas or the tissues changed behaviour.
- The same aged mice showed reduced adiposity and smaller adipocytes, less liver lipid, higher energy expenditure, better metabolic flexibility and better cognitive performance[1].
- In aged rats, TUDCA given intravenously at 300 mg/kg with an oral probiotic for one week reduced liver cellular degeneration, lymphatic infiltration and fibrosis, and lowered NLRP3 and ASC immunoreactivity[2]. The TUDCA arm was intravenous, and the probiotic arm paradoxically raised AST and LDH.
- TUDCA increased neural stem cell proliferation and early neurogenesis in the subventricular zone of adult rats but not in dentate gyrus-derived cells[3], and it was delivered intracerebroventricularly, straight into the brain’s fluid.
- No human trial has tested TUDCA against any ageing, healthspan or longevity endpoint. No study in any species has measured lifespan on TUDCA.
The Aged Mouse Metabolic Study, and the Detail That Reframes It
The most directly relevant paper is from Scientific Reports in 2022[1]. Eighteen-month-old male C57BL/6 mice, which is genuinely old for a mouse, received 300 mg/kg TUDCA or vehicle. Hyperinsulinemia was attenuated and glucose homeostasis improved, adiposity fell along with adipocyte size, liver lipid accumulation decreased, energy expenditure and metabolic flexibility rose, and cognitive performance improved.
That is a broad set of favourable outcomes and it is fair to call it impressive in an animal that age. Then read the mechanism the authors identified: the effect on glucose and insulin came from enhanced liver insulin-degrading enzyme expression and increased insulin clearance.
This is important and widely misread. A lower circulating insulin level can mean the body needs less insulin, which is what people assume, or it can mean insulin is being destroyed faster, which is what was measured here. Those are different physiological states that produce the same number on a blood test. The same caveat appears in the type 1 diabetes literature discussed on the beta cell page, where a large share of a glucose improvement also came from reduced insulin clearance rather than new insulin production.
It does not make the finding worthless. Chronic hyperinsulinemia is itself associated with poor outcomes and clearing it faster may well be beneficial. It does mean the result should not be described as improved insulin sensitivity, and it should not be read across to the separate question covered on the insulin resistance page.
Two Studies That Did Not Use the Gut
A 2024 paper in Archives of Gerontology and Geriatrics examined liver health in elderly male Sprague-Dawley rats given TUDCA and a probiotic preparation daily for one week[2]. Histology showed significant reductions in cellular degeneration, lymphatic infiltration and hepatic fibrosis, and immunoreactivity for the inflammasome components NLRP3 and ASC fell.
TUDCA in that study was administered intravenously at 300 mg/kg. An intravenous dose bypasses absorption entirely, which removes precisely the limitation that governs what an oral capsule can achieve. It is also worth reporting the study’s own awkward finding: the probiotic reduced some inflammasome-related gene expression while paradoxically increasing AST and LDH, two markers of tissue injury. A combination study with a mixed signal in one arm is weak ground for a claim about either component.
The neurogenesis work has the same issue in a more extreme form. A 2018 study in Molecular Neurobiology found TUDCA increased neural stem cell proliferation, self-renewal and neural differentiation, with higher expression of mitochondrial biogenesis proteins and mitochondrial antioxidant responses[3]. In adult rats the in vivo confirmation came from intracerebroventricular administration, injecting the compound directly into the cerebrospinal fluid.
That study also contains a specificity finding that rarely gets quoted: the effect appeared in subventricular zone stem cells and not in cells from the hippocampal dentate gyrus. The dentate gyrus is the neurogenic niche most associated with learning and memory in adults. So the result is regionally selective, in a direction that makes the cognitive extrapolation weaker rather than stronger.
What the Mechanism Stories Have in Common
Three of the recurring ageing mechanisms show up across this small literature, and they are consistent with the rest of the site. Chronic low-grade inflammation, indexed here by NLRP3 inflammasome activity[2]. Mitochondrial decline, addressed by the biogenesis findings[3] and covered on the mitochondrial function page. And proteostasis, the ER stress axis that is TUDCA’s core mechanism.
A 2024 review in Frontiers in Neuroscience assembles the neurodegenerative version of this argument for Alzheimer’s disease, proposing reduced amyloid beta deposition, regulation of apoptotic pathways, prevention of tau hyperphosphorylation, synaptic protection, anti-inflammatory effects and improved metabolic disorders[4]. It is a review, which means it organises existing hypotheses rather than testing one, and the specific Alzheimer’s evidence has its own page here.
Coherence across mechanisms is a genuine point in a compound’s favour, because unrelated findings that share a plausible cause are less likely to all be noise. It is not the same as evidence of an effect on ageing, and the distinction is where most longevity marketing lives.
Why 300 mg/kg in a Mouse Is Not a Dose You Can Use
Two of the three animal studies above used 300 mg/kg. For an 80 kg human, naive bodyweight scaling gives 24 grams a day, which is roughly fifty times the top of the range on the dosing page and not a quantity anyone takes.
Bodyweight scaling is the wrong arithmetic anyway. Metabolic rate does not scale linearly with mass, so allometric conversion gives a much smaller figure, and conversions of that kind generate hypotheses for a first human dose rather than equivalences. The deeper problem is the route. An intravenous dose and an intracerebroventricular dose are not doses of an oral supplement in any sense; they are ways of guaranteeing a tissue concentration that a capsule cannot be assumed to reach.
The 2022 aged mouse study is the one whose findings are most transferable in principle, because the outcomes are systemic and metabolic rather than delivered to a single organ. Even there, the honest statement is that old mice given a large dose of TUDCA had better metabolic and cognitive measures, and that no one has tested whether an old human taking a normal dose gets anything comparable.
What Would Count as Evidence
A human trial with an ageing-relevant endpoint. Fasting insulin and a measure of insulin clearance would be a reasonable start given the mouse mechanism, in older adults, over months, against placebo. None exists.
Failing that, a lifespan study in any species. Despite TUDCA being routinely described as a longevity compound, no study has measured survival on TUDCA as an endpoint, in mice or otherwise. That is a striking gap for a compound sold on this premise, and it is cheap to close, which makes its absence informative.
In the meantime, the defensible reasons to take TUDCA are the ones with human evidence behind them, which means cholestatic liver disease. If you are taking it inside a longevity stack, the realistic position is that you are betting on mechanism, that the bet is not unreasonable, and that the long-term safety data are thinner than the enthusiasm. Interactions with the other components of a stack are worth checking on the interactions page.
Nothing on this page is medical advice. Ageing is not a condition a supplement has been shown to treat, and age-related changes in glucose, liver function or cognition deserve proper assessment rather than self-management.
Frequently Asked Questions
Is TUDCA proven to extend lifespan?
No. No study in any species has measured lifespan or survival on TUDCA as an endpoint. The ageing literature consists of short interventions in old animals measuring metabolic, hepatic and neural markers, the longest of the key studies running one week[2]. Describing TUDCA as a longevity compound goes well beyond what has been tested.
What happened in the aged mouse study?
Eighteen-month-old male mice given 300 mg/kg TUDCA showed attenuated hyperinsulinemia, better glucose homeostasis, less adiposity and liver fat, higher energy expenditure and metabolic flexibility, and better cognitive performance[1]. The glucose benefit was traced to higher liver insulin-degrading enzyme expression and faster insulin clearance, meaning insulin was being removed more quickly rather than needed less.
Does TUDCA promote new brain cell growth?
In rats, it increased neural stem cell proliferation, self-renewal and differentiation in the subventricular zone, along with mitochondrial biogenesis markers[3]. Two limits matter: the in vivo dosing was intracerebroventricular, delivered directly into cerebrospinal fluid, and the effect did not appear in dentate gyrus-derived stem cells, the niche most associated with adult learning and memory.
Can I scale the animal doses to a human dose?
Not usefully. Two of the key studies used 300 mg/kg, which naive bodyweight scaling would turn into roughly 24 grams a day for an 80 kg adult, around fifty times the usual supplement range. Allometric scaling gives a far lower number, and either way the route is the bigger obstacle: intravenous and intracerebroventricular dosing bypass the absorption limits that determine what an oral capsule delivers.
References
- The bile acid TUDCA reduces age-related hyperinsulinemia in mice. Sci Rep (2022).
- Promoting longevity in aged liver through NLRP3 inflammasome inhibition using tauroursodeoxycholic acid (TUDCA) and SCD probiotics. Arch Gerontol Geriatr (2024).
- Tauroursodeoxycholic Acid Enhances Mitochondrial Biogenesis, Neural Stem Cell Pool, and Early Neurogenesis in Adult Rats. Mol Neurobiol (2018).
- Tauroursodeoxycholic acid: a bile acid that may be used for the prevention and treatment of Alzheimer’s disease. Front Neurosci (2024).
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
